Head and Neck

Afatinib

Description: Afatinib is a tyrosine kinase inhibitor that blocks irreversibly EGFR and HER2. Two Phase III studies are enrolling patients. First is evaluating efficacy and safety of Afatinib as adjuvant treatment. Patients with primary unresected loco-regionally advanced (stages III, IVA, IVB) Head and Neck Cancer will be randomized to receive Afatinib or placebo after chemo-radiotherapy. Second Phase III study is evaluating the efficacy and safety of oral Afatinib versus intravenous Methotrexate in patients with recurrent and/ or metastatic Head and neck Cancer who have progressed after platinum-based therapy.
Type(s) of Cancer: Head and Neck
Study Phase(s): Phase III
Contact: Epp Goodwin at (210) 450-5798

Cetuximab+Docetaxel+Cisplatin+Bevacizumab+XRT

Description:

This Phase II study of cetuximab in combination with docetaxel, cisplatin, bevacizumab and radiation in patients with locally advanced head and neck cancer. Cetuximab binds to epidermal growth factor receptor and blocks the activity of epidermal growth factor.


Type(s) of Cancer: Head and Neck
Study Phase(s): Phase II
Contact: Epp Goodwin at (210) 450-5798

E1305

Description:

In this Phase III study patients with recurrent or metastatic Head and Neck Cancer will be randomized to receive standard platinum-based chemotherapy with or without Bevacizumab. Standard regimen can be Docetaxel+Cisplatin(Carbo) or Cisplatin (Carbo)+ 5-FU.


Type(s) of Cancer: Head and Neck
Study Phase(s): Phase III
Contact: Epp Goodwin at (210) 450-5798